Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study. (February 2014)

• Record Type: Journal Article
• Authors: Kita, Mariko; Fox, Robert J; Phillips, J Theodore; Hutchinson, Michael; Havrdova, Eva; Sarda, Sujata P; Agarwal, Sonalee; Kong, Jessica; Zhang, Annie; Viglietta, Vissia; Sheikh, Sarah I; Seidman, Emily; Dawson, Katherine T
• Is Part Of: Multiple sclerosis. Volume 20:Number 2(2014)
• Page Start: 253
• Page End: 257
• Publication Date: 2014-02
• Subjects: Multiple sclerosis -- relapsing–remitting -- BG-12 -- dimethyl fumarate -- quality of life -- glatiramer acetate -- randomized controlled trial; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458513507818
• Languages: English
• ISSNs: 1352-4585

Abstract

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing–remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.